Show simple item record

dc.contributor.authorCummings, Jeffrey
dc.contributor.authorRanson, Malcolm R
dc.contributor.authorButt, Fouziah
dc.contributor.authorMoore, David
dc.contributor.authorDive, Caroline
dc.date.accessioned2009-06-12T15:39:58Z
dc.date.available2009-06-12T15:39:58Z
dc.date.issued2007-11
dc.identifier.citationQualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. 2007, 60 (6):921-4 Cancer Chemother. Pharmacol.en
dc.identifier.issn0344-5704
dc.identifier.pmid17333190
dc.identifier.doi10.1007/s00280-007-0437-4
dc.identifier.urihttp://hdl.handle.net/10541/70420
dc.description.abstractPURPOSE: M30 and M65 ELISAs are proposed as surrogate biomarkers of tumour cell death in patients and are being applied increasingly in the pharmacodynamic (PD) evaluation of anticancer drugs during clinical trials. In the absence of such data, we have studied the long-term stability of the antigens of both assays in plasma of cancer patients stored at -80 degrees C over 2 years. RESULTS: No evidence was detected of degradation in the M65 antigen. However, in a proportion of patients significant increases in levels of M30 antigen were detected CONCLUSION: Plasma samples for M65 analysis can be stored at -80 degrees C for 2 years; however, caution is recommended when considering long-term storage of samples for the M30 assay.
dc.language.isoenen
dc.subjectCancer Antigensen
dc.subjectCancer Proteinsen
dc.subjectTumour Markersen
dc.subject.meshAntigens, Neoplasm
dc.subject.meshAntineoplastic Agents
dc.subject.meshApoptosis
dc.subject.meshCell Death
dc.subject.meshCentrifugation
dc.subject.meshDrug Screening Assays, Antitumor
dc.subject.meshEnzyme-Linked Immunosorbent Assay
dc.subject.meshFreezing
dc.subject.meshHumans
dc.subject.meshKeratin-18
dc.subject.meshNeoplasm Proteins
dc.subject.meshOligonucleotides
dc.subject.meshSpecimen Handling
dc.subject.meshTime Factors
dc.subject.meshTumor Markers, Biological
dc.titleQualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasmaen
dc.typeArticleen
dc.contributor.departmentClinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester, M20 4BX, England. jcummings@picr.man.ac.uken
dc.identifier.journalCancer Chemotherapy and Pharmacologyen
html.description.abstractPURPOSE: M30 and M65 ELISAs are proposed as surrogate biomarkers of tumour cell death in patients and are being applied increasingly in the pharmacodynamic (PD) evaluation of anticancer drugs during clinical trials. In the absence of such data, we have studied the long-term stability of the antigens of both assays in plasma of cancer patients stored at -80 degrees C over 2 years. RESULTS: No evidence was detected of degradation in the M65 antigen. However, in a proportion of patients significant increases in levels of M30 antigen were detected CONCLUSION: Plasma samples for M65 analysis can be stored at -80 degrees C for 2 years; however, caution is recommended when considering long-term storage of samples for the M30 assay.


This item appears in the following Collection(s)

Show simple item record